Almirall

Almirall EBIT

The EBIT of Almirall (ALM.MC) as of Oct 4, 2026 is 67.71 M EUR. In the previous year, EBIT was 36.09 M EUR — a change of 87.65% (higher).

EBIT

67.71 MEUR

YoY

87.65%

Last updated:

In 2026, Almirall's EBIT was 67.71 M EUR, a 87.65% increase from the 36.09 M EUR EBIT recorded in the previous year.

The Almirall EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-5.26 M EUR
Jan 1, 2024
36.09 M EUR
Jan 1, 2025
67.71 M EUR
Jan 1, 2026 (e)
152.52 M EUR
Jan 1, 2027 (e)
203.48 M EUR
Jan 1, 2028 (e)
258.59 M EUR
Jan 1, 2029 (e)
310.86 M EUR
Jan 1, 2030 (e)
339.61 M EUR
The Almirall EBIT history
YEAREBITYoY
est339.61 MEUR+9.25%
est310.86 MEUR+20.22%
est258.59 MEUR+27.09%
est203.48 MEUR+33.41%
est152.52 MEUR+125.23%
67.71 MEUR+87.65%
36.09 MEUR-785.52%
-5.26 MEUR-111.23%
46.87 MEUR-55.52%
105.38 MEUR+14.17%
92.30 MEUR-38.43%
149.91 MEUR+72.33%
86.99 MEUR-129.01%
-299.85 MEUR-329.77%
130.50 MEUR-22.45%
168.28 MEUR-66.99%
509.75 MEUR-704.32%
-84.35 MEUR-232.94%
63.45 MEUR-17.92%
77.30 MEUR-49.93%
154.40 MEUR-13.79%
179.10 MEUR-80.16%
902.80 MEUR+155.60%
353.21 MEUR+164.17%
133.71 MEUR—
Access this data via the Eulerpool API

Almirall Revenue

Almirall Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
894.52 M EUR
-5.26 M EUR
-38.47 M EUR
Jan 1, 2024
985.72 M EUR
36.09 M EUR
10.15 M EUR
Jan 1, 2025
1.11 B EUR
67.71 M EUR
46.20 M EUR
Jan 1, 2026 (e)
1.23 B EUR
152.52 M EUR
84.51 M EUR
Jan 1, 2027 (e)
1.35 B EUR
203.48 M EUR
113.63 M EUR
Jan 1, 2028 (e)
1.47 B EUR
258.59 M EUR
149.57 M EUR
Jan 1, 2029 (e)
1.59 B EUR
310.86 M EUR
185.40 M EUR
Jan 1, 2030 (e)
1.66 B EUR
339.61 M EUR
203.51 M EUR

Almirall Margins

Almirall stock margins

The Almirall margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Almirall. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Almirall.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
64.52 %
-0.59 %
-4.30 %
Jan 1, 2024
77.88 %
3.66 %
1.03 %
Jan 1, 2025
41.21 %
6.11 %
4.17 %
Jan 1, 2026 (e)
41.21 %
12.43 %
6.89 %
Jan 1, 2027 (e)
41.21 %
15.09 %
8.43 %
Jan 1, 2028 (e)
41.21 %
17.59 %
10.17 %
Jan 1, 2029 (e)
41.21 %
19.56 %
11.66 %
Jan 1, 2030 (e)
41.21 %
20.46 %
12.26 %

Almirall Stock analysis

What does Almirall do? The company Almirall SA is a globally operating pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943 by Antonio Gallardo Ballart, the company has since become one of the leading companies in the field of dermatology and respiratory diseases. Almirall specializes in the development, manufacturing, and marketing of medications used in the treatment of skin conditions such as psoriasis or eczema, as well as respiratory diseases such as asthma or chronic bronchitis. The company focuses on close collaboration with doctors and patients to achieve the best possible therapeutic success. Almirall's business model is based on collaboration with other pharmaceutical companies to develop and bring innovative medications to the market. The company has its own research and development departments and also conducts clinical trials to test the safety and efficacy of new medications. Additionally, Almirall operates its own network of distribution and marketing partners to distribute its products worldwide. Almirall is organized into three divisions: dermatology, respiratory diseases, and other therapeutic areas. The dermatology division includes the development and marketing of medications for the treatment of skin conditions such as psoriasis and eczema. Some examples of products in this division are Skilarence, a medication for the treatment of moderate to severe psoriasis, and Kigozi, a topical medication for the treatment of atopic dermatitis. The respiratory diseases division includes the development and marketing of medications for the treatment of asthma and chronic bronchitis. The company offers a wide range of medications in this area that can be used in inhalation or tablet therapy. Some of the well-known products in this division are Alvesco, an inhaled corticosteroid for the treatment of asthma, and Ebastel, a medication for the treatment of allergic reactions. In other therapeutic areas, Almirall is involved in the development of new medications for the treatment of diseases such as ulcerative colitis or schizophrenia. For example, the company has developed Sativex, a cannabis-based medication for the treatment of multiple sclerosis-related spasticity, which is already approved in several countries. Throughout its history, Almirall has received numerous awards and recognition, including for the development of innovative medications and its work in the field of sustainability and corporate social responsibility. Through its commitment to research and development and collaboration with other pharmaceutical companies, Almirall will continue to play an important role in the global pharmaceutical industry market. Almirall is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Almirall's EBIT

Almirall's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Almirall's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Almirall's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Almirall’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Almirall stock

EBIT of Almirall is 67.71 M EUR in 2026.

EBIT of Almirall changed from 36.09 M EUR to 67.71 M EUR, representing a 87.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Almirall since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Almirall historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Almirall

All Key Metrics — Almirall